KalVista Pharmaceuticals Inc. (KALV) is all set to be acquired by Chiesi Group, an international research-focused biopharmaceutical group, for $27.00 per share in cash, representing an equity consideration of roughly $1.9 billion.
The flagship drug of KalVista is EKTERLY, the first and only oral on-demand treatment for Hereditary Angioedema (HAE). The US commercial launch of EKTERLY was initiated on July 7, 2025. The drug generated net product revenue of $49.1 million in 2025.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.